Patented Drugs Market By Dosage Form (Solid Drug Product, Liquid Drug Product, Others), By Indication (Cardiovascular Diseases, Cancer, Autoimmune Diseases, Others), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Patented Drugs Market

The patented drugs market is likely to experience a significant growth rate of 6.0% from 2023-2032 owing to increase in demand from pharmaceutical sector–

A patent is a form of exclusive right granted for an invention. The property rights granted through the various patent organization across the globe such as U.S. Patent and Trademark Office (USPTO), and various others. The process of obtaining a patent occur at any stage during the development of a drug. The duration of patent can vary depending on the type of patent and the jurisdiction in which it is granted. Utility patents has a duration of 20 years from the filing date of patent application. 

Key factors driving the growth of the patented drugs market include increase in research and development spending, surge in healthcare spending, and rise in development of novel medicines. Research and development investments fuel innovation by supporting extensive scientific research, exploratory studies, and preclinical investigations. These activities are aimed at identifying novel drug targets, understanding disease mechanisms, and discovering potential therapeutic lead molecules. 

Furthermore, Increase in healthcare spending that allows for better access to healthcare services, including prescription medications. As more individuals have access to healthcare coverage and can afford necessary treatments, the demand for innovative and effective drugs increases. This increased patient access creates a higher market for patented drugs, thereby driving the market growth. For instance, American Medical Association (AMA), reported that U.S. health spending increased by 2.7% in 2021 to $4.3 trillion per capita. In addition, technological advancements such as genomics facilitate the development of novel drugs which further contribute towards the market growth.

The patented drugs market growth is driven by increase in sell of patented drugs such as Humira  Keytruda, Comirnaty, and others. For instance, Humira is a patented drug that belongs to a class of medications called as tumor necrosis factor (TNF) inhibitors. It is primarily used to treat various autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis. Humira generated $21,237 million revenue in 2022. Similarly, Keytruda is primarily used in the treatment of various types of cancer. It has generated $20,937 million in 2022. Thus, revenue generated from increased sales fuels the growth of the patented drugs market by facilitating ongoing investments in new drug discovery and development.  

The rise in chronic conditions such as cardiovascular diseases, diabetes, cancer, and respiratory disorders contributes to the growing demand for innovative medications. For instance, the increasing prevalence of diabetes worldwide has driven the development of patented drugs like insulin analogs and oral antidiabetic agents, which offer improved glucose control and management compared to older treatments. In addition, the prevalence of various types of cancer continues to rise globally. The development of targeted therapies and immunotherapies, such as monoclonal antibodies and immune checkpoint inhibitors, has revolutionized cancer treatment. These patented drugs provide more precise and personalized approaches to cancer therapy, improving outcomes for patients.

Rare diseases affect a small percentage of the population but collectively impact a significant number of individuals. For instance, according to AstraZeneca, about 400 million people around the world are affected by rare disease and half of the affected population are children. Therefore, development of patented drugs for rare diseases has gained attention due to the unmet medical needs of these patient populations. Examples include drugs like enzyme replacement therapies for lysosomal storage disorders or gene therapies for rare genetic disorders. This has increased the demand for patented drugs which, in turn, contribute toward the market growth. Moreover, strong intellectual property rights allows companies to recoup their investments in research and development and generate profits.

The patented drugs market is segmented on the basis of dosage form, indication, distribution channel, and region. On the basis of dosage form, the market is classified into oral drug product, liquid drug product, and others. On the basis of indication the market is segmented into cardiovascular diseases, cancer, autoimmune diseases, diabetes, and others. On the basis of distribution channel the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. 

On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players profiled in the study include Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, Biogen, Bayer AG, AstraZeneca, and Astella Pharma. 

Key Market Insights 

By dosage form, the liquid drug product segment was the largest revenue contributor to the market in 2022 and is estimated to reach $845,346.4 million by 2032.

On the basis of indication, the cancer segment dominated the global market in 2022. However, others segment is expected to register fastest CAGR of 6.6% during the forecast period.

By distribution channel, the drug stores and retail pharmacies segment dominated the global market in 2022. 

Based on region, North America garnered the largest revenue share in 2022. However Asia-Pacific is anticipated to grow at the highest CAGR of 7.0% during the forecast period.

 

Overview

The patented drugs market was valued at $814.5 billion in 2022 and is estimated to reach $1,456.5 billion by 2032, exhibiting a CAGR of 6.0% from 2023 to 2032. Patented drugs are pharmaceutical products that have been granted legal protection through a patent by government authorities, such as U.S. Patent and Trademark Office (USPTO), Intellectual Property Office, Japan Patent Office, and others. A patent is a legal protection that gives the patent holder exclusive rights to manufacture, use, and sell the patented drug for 20 years from the filing date of the patent application. During this period, other companies are prohibited from producing or marketing the same drug without permission from the patent holder. Patented drugs are the result of significant research and development efforts, and patents serve as a mechanism to protect and incentivize innovation in the pharmaceutical industry. 

The patented drugs market growth is driven by increase in the number of research activities for development of new drugs, advancement in biotechnology and 3D modeling, and rise in people suffering from chronic diseases. Researchers explore various disease mechanisms, molecular pathways, and drug targets to identify potential areas for therapeutic intervention. This creates opportunities for the development of new drugs which drives the growth of patented drugs market. Furthermore, the prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, respiratory disorders, and neurological conditions, has been steadily rising globally. For instance, in 2021 American Cancer Society (ACS), estimated that about 1.9 million new cancer cases were diagnosed in the U.S. The available patented drugs for cancer include Avastin, KYPROLIS, IBRANCE, and others. This rise in chronic diseases has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the patented drugs market.  

In addition, the availability of robust regulatory authorities such as U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) determines the drug approval process and grant market exclusivity to pharmaceuticals. This exclusivity period provide advantages for pharmaceutical companies, enabling them to recover their investment and generate revenue from patented drugs. Furthermore, increase in number of patent application filing in 2022 further boost the growth of the patented drugs market. For instance, in 2022, European Patent Office (EPO), received a total of 193,460 applications. It was also reported that patent activity in pharmaceuticals increased by 1% as compared to 2021. 

However, entry of generic versions of the drug at lower prices after patent expiration limit the growth of the patented drugs market. The availability of cheaper alternatives may impact the demand for patented drugs. Furthermore, high costs associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new patented drugs thereby impacting the market growth. On the other hand, surge in technological advancements, such as precision medicine, genomics, proteomics, and targeted therapies, are revolutionizing drug discovery and development. These advancements enable the development of more effective and patented drugs during the forecast period. 

The patented drugs market is segmented on the basis of dosage form, indication, distribution channel, and region. On the basis of dosage form, the market is classified into solid drug product, liquid drug product, and others. Others segments include semi-solid drug and gaseous drug. As per indication, the market is categorized into cardiovascular diseases, cancer, autoimmune diseases, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the global patented drugs market are AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bayer AG, Johnson & Johnson, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Biogen. Key players operating in the market have adopted patent and patent extension as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patented drugs market analysis from 2022 to 2032 to identify the prevailing patented drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the patented drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global patented drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

● SWOT Analysis

Key Market Segments

○ AbbVie Inc

Scope of Patented Drugs Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in investment in research and development activities

3.4.1.2. Surge in disease burden

3.4.2. Restraints

3.4.2.1. High cost of patented drugs

3.4.3. Opportunities

3.4.3.1. Strong intellectual property rights

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Solid Drug Product

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Liquid Drug Product

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Cardiovascular Diseases

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Cancer

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Autoimmune Diseases

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Others

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug Store and Retail Pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Pharmacies

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Dosage Form

7.2.3. Market size and forecast, by Indication

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Dosage Form

7.2.5.1.3. Market size and forecast, by Indication

7.2.5.1.4. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Dosage Form

7.2.5.2.3. Market size and forecast, by Indication

7.2.5.2.4. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Dosage Form

7.2.5.3.3. Market size and forecast, by Indication

7.2.5.3.4. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Dosage Form

7.3.3. Market size and forecast, by Indication

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Dosage Form

7.3.5.1.3. Market size and forecast, by Indication

7.3.5.1.4. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Dosage Form

7.3.5.2.3. Market size and forecast, by Indication

7.3.5.2.4. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Dosage Form

7.3.5.3.3. Market size and forecast, by Indication

7.3.5.3.4. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Dosage Form

7.3.5.4.3. Market size and forecast, by Indication

7.3.5.4.4. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Dosage Form

7.3.5.5.3. Market size and forecast, by Indication

7.3.5.5.4. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Dosage Form

7.3.5.6.3. Market size and forecast, by Indication

7.3.5.6.4. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Dosage Form

7.4.3. Market size and forecast, by Indication

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Dosage Form

7.4.5.1.3. Market size and forecast, by Indication

7.4.5.1.4. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Dosage Form

7.4.5.2.3. Market size and forecast, by Indication

7.4.5.2.4. Market size and forecast, by Distribution Channel

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Dosage Form

7.4.5.3.3. Market size and forecast, by Indication

7.4.5.3.4. Market size and forecast, by Distribution Channel

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Dosage Form

7.4.5.4.3. Market size and forecast, by Indication

7.4.5.4.4. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Dosage Form

7.4.5.5.3. Market size and forecast, by Indication

7.4.5.5.4. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Dosage Form

7.4.5.6.3. Market size and forecast, by Indication

7.4.5.6.4. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Dosage Form

7.5.3. Market size and forecast, by Indication

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Dosage Form

7.5.5.1.3. Market size and forecast, by Indication

7.5.5.1.4. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Dosage Form

7.5.5.2.3. Market size and forecast, by Indication

7.5.5.2.4. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Dosage Form

7.5.5.3.3. Market size and forecast, by Indication

7.5.5.3.4. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Dosage Form

7.5.5.4.3. Market size and forecast, by Indication

7.5.5.4.4. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. AbbVie Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. Amgen Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Pfizer Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Novartis AG

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. AstraZeneca plc

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Bayer AG

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. Johnson & Johnson

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. F. Hoffmann-La Roche AG

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Biogen

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Astellas Pharma Inc.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 02. PATENTED DRUGS MARKET FOR SOLID DRUG PRODUCT, BY REGION, 2022-2032 ($MILLION)

TABLE 03. PATENTED DRUGS MARKET FOR LIQUID DRUG PRODUCT, BY REGION, 2022-2032 ($MILLION)

TABLE 04. PATENTED DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 06. PATENTED DRUGS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)

TABLE 07. PATENTED DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)

TABLE 08. PATENTED DRUGS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)

TABLE 09. PATENTED DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 10. GLOBAL PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 11. PATENTED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 12. PATENTED DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 13. PATENTED DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 14. PATENTED DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 18. NORTH AMERICA PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 19. U.S. PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 20. U.S. PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 21. U.S. PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 22. CANADA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 23. CANADA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 24. CANADA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 25. MEXICO PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 26. MEXICO PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 27. MEXICO PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 28. EUROPE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 29. EUROPE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 30. EUROPE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 31. EUROPE PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 32. GERMANY PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 33. GERMANY PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 34. GERMANY PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 35. FRANCE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 36. FRANCE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 37. FRANCE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 38. UK PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 39. UK PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 40. UK PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 41. ITALY PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 42. ITALY PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 43. ITALY PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 44. SPAIN PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 45. SPAIN PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 46. SPAIN PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 49. REST OF EUROPE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 53. ASIA-PACIFIC PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 54. JAPAN PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 55. JAPAN PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 56. JAPAN PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 57. CHINA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 58. CHINA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 59. CHINA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 60. INDIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 61. INDIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 62. INDIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 63. AUSTRALIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 64. AUSTRALIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 65. AUSTRALIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 68. SOUTH KOREA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 72. LAMEA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 73. LAMEA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 74. LAMEA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 75. LAMEA PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 76. BRAZIL PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 77. BRAZIL PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 78. BRAZIL PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 81. SAUDI ARABIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 84. SOUTH AFRICA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 87. REST OF LAMEA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 88. ABBVIE INC.: KEY EXECUTIVES

TABLE 89. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 90. ABBVIE INC.: PRODUCT SEGMENTS

TABLE 91. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 92. AMGEN INC.: KEY EXECUTIVES

TABLE 93. AMGEN INC.: COMPANY SNAPSHOT

TABLE 94. AMGEN INC.: PRODUCT SEGMENTS

TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 96. PFIZER INC.: KEY EXECUTIVES

TABLE 97. PFIZER INC.: COMPANY SNAPSHOT

TABLE 98. PFIZER INC.: PRODUCT SEGMENTS

TABLE 99. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 100. PFIZER INC.: KEY STRATERGIES

TABLE 101. NOVARTIS AG: KEY EXECUTIVES

TABLE 102. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 103. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 104. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 105. NOVARTIS AG: KEY STRATERGIES

TABLE 106. ASTRAZENECA PLC: KEY EXECUTIVES

TABLE 107. ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 108. ASTRAZENECA PLC: PRODUCT SEGMENTS

TABLE 109. ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 110. BAYER AG: KEY EXECUTIVES

TABLE 111. BAYER AG: COMPANY SNAPSHOT

TABLE 112. BAYER AG: PRODUCT SEGMENTS

TABLE 113. BAYER AG: PRODUCT PORTFOLIO

TABLE 114. JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 115. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 116. JOHNSON & JOHNSON: PRODUCT SEGMENTS

TABLE 117. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 118. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES

TABLE 119. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

TABLE 120. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS

TABLE 121. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO

TABLE 122. BIOGEN: KEY EXECUTIVES

TABLE 123. BIOGEN: COMPANY SNAPSHOT

TABLE 124. BIOGEN: PRODUCT SEGMENTS

TABLE 125. BIOGEN: PRODUCT PORTFOLIO

TABLE 126. BIOGEN: KEY STRATERGIES

TABLE 127. ASTELLAS PHARMA INC.: KEY EXECUTIVES

TABLE 128. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT

TABLE 129. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS

TABLE 130. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. PATENTED DRUGS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF PATENTED DRUGS MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN PATENTED DRUGS MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. MODERATE BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL PATENTED DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR SOLID DRUG PRODUCT, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR LIQUID DRUG PRODUCT, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. PATENTED DRUGS MARKET, BY INDICATION, 2022(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. PATENTED DRUGS MARKET BY REGION, 2022(%)

FIGURE 24. U.S. PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 25. CANADA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 26. MEXICO PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 27. GERMANY PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 28. FRANCE PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 29. UK PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 30. ITALY PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 31. SPAIN PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 32. REST OF EUROPE PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 33. JAPAN PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 34. CHINA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 35. INDIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 36. AUSTRALIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 37. SOUTH KOREA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 38. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 39. BRAZIL PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 40. SAUDI ARABIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 41. SOUTH AFRICA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 42. REST OF LAMEA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47. COMPETITIVE DASHBOARD

FIGURE 48. COMPETITIVE HEATMAP: PATENTED DRUGS MARKET

FIGURE 49. TOP PLAYER POSITIONING, 2022

FIGURE 50. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 51. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 52. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 53. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 54. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 62. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)

FIGURE 65. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 67. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 68. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 69. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 70. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 71. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 72. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%